Literature DB >> 6404382

Effect of doxapram on heavy sedation produced by intravenous diazepam.

C J Allen, K R Gough.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6404382      PMCID: PMC1547413          DOI: 10.1136/bmj.286.6372.1181-a

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


× No keyword cloud information.
  5 in total

1.  Doxapram antagonism of meperidine-induced respiratory depression.

Authors:  S Ramamurthy; S N Steen; A P Winnie
Journal:  Anesth Analg       Date:  1975 May-Jun       Impact factor: 5.108

2.  Potencies of doxapram and hypoxia in stimulating carotid-body chemoreceptors and ventilation in anesthetized cats.

Authors:  R A Mitchell; D A Herbert
Journal:  Anesthesiology       Date:  1975-05       Impact factor: 7.892

3.  Selective respiratory stimulating action of doxapram compared to pentylenetetrazaol.

Authors:  K Hirsh; S C Wang
Journal:  J Pharmacol Exp Ther       Date:  1974-04       Impact factor: 4.030

4.  Hastening of arousal after general anaesthesia with doxapram hydrochloride.

Authors:  P K Gupta; J W Dundee
Journal:  Br J Anaesth       Date:  1973-05       Impact factor: 9.166

5.  Evaluation of doxapram for arousal from general anaesthesia in outpatients.

Authors:  G S Robertson; D M MacGregor; C J Jones
Journal:  Br J Anaesth       Date:  1977-02       Impact factor: 9.166

  5 in total
  3 in total

Review 1.  Clinical features, pathogenesis and management of drug-induced seizures.

Authors:  G Zaccara; G C Muscas; A Messori
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

Review 2.  Benzodiazepine poisoning. Clinical and pharmacological considerations and treatment.

Authors:  P Gaudreault; J Guay; R L Thivierge; I Verdy
Journal:  Drug Saf       Date:  1991 Jul-Aug       Impact factor: 5.606

3.  Psychomotor and clinical assessment of flumazenil as an antagonist of midazolam.

Authors:  K M Bill; J P Fee; R S Clarke
Journal:  J R Soc Med       Date:  1991-05       Impact factor: 18.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.